Fadi Haddad: P3 trial of DAC-10 vs 7+3 in older AML pts followed by ASCT

Fadi Haddad, Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, shared the following post by The Lancet Haematology, on Twitter adding the following:

“P3 trial of DAC-10 vs 7+3 in older AML pts followed by ASCT:

• Similar 4y OS: 26% vs 30%
• Better safety profile of DAC-10

Combos with VEN & targeted therapies are moving the field forward
Clad-LDAC-VEN very effective & safe in older pts Tapan Kadia”

Quoting The Lancet Haematology: 

“NEW: 10-day decitabine vs 3+7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial”

Source: Fadi Haddad/Twitter and The Lancet Haematology/Twitter